The potential interplay or distinct impact of mutations within the EGFR pathway (EGFR, KRAS, NRAS, BRAF, PI3KCA), along with polymorphisms in genes related to 5-fluorouracil and oxaliplatin (DPYD, TYMS, GSTP1, MTHFR, ABCB1), on the prognosis of colorectal cancer remains uncharted territory. The gene discussed is EGFR; the disease is colorectal cancer.